Why the study?
Does deletion or replacement of the second EGF-like domain of protein S reduce APC cofactor activity in vitro?
Does deletion or replacement of the second EGF-like domain of protein S reduce APC cofactor activity in vitro?
The second EGF-like domain of protein S is specifically required for its APC cofactor activity.
Does not alter clinical protein S assessment; leaves open EGF2-targeted modulation for future coagulation research.
Human protein S (PS), a cofactor of anticoagulant-activated protein C (APC), is a modular protein containing 4 epidermal growth factor (EGF)-like domains. EGF1 appears to mediate PS interaction with APC, but the roles of EGFs 2, 3, and 4 are less clear. We synthesized PS variants lacking single EGF domains (EGF2, 3, or 4) and assessed their APC cofactor activity in a factor Va inactivation assay. The variant lacking EGF2 (variant 134) showed the most dramatic loss of activity (approximately 10% of recombinant wild-type PS activity). Replacement of EGF2 by an additional EGF3 (variant 1334) resulted in a comparable loss of activity, suggesting that the loss of a specific rather than "spacer" function of EGF2 was responsible. We confirmed that the variant 134 had a functional gamma-carboxyglutamic acid (Gla) domain and that EGF1 was correctly folded. This is the first clear evidence that EGF2 is required for the expression of PS activity.
No takes yet. Share an insight, caveat, or question.
Mille-Baker et al. (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: